LENZ Therapeutics, Inc. (LENZ)
Nasdaq · Healthcare · Biotechnology
$3.59+0.28%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $113M
- 52-week range
- $3.46 – $49.25
- 52-week change
- −92.24%
- EPS (trailing)
- −$4.13
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $19.1M
- Net income
- −$82.1M
- Operating margin
- −477.5%
- Diluted EPS
- −$2.85
- Free cash flow
- −$70.0M
From the company’s annual report on SEC EDGAR.
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Headquarters: Solana Beach, United States · 152 employees · lenz-tx.com